Comparative cardiovascular effectiveness of empagliflozin versus dapagliflozin in adults with treated type 2 diabetes: a target trial emulation
Bonnesen K, Heide-Jørgensen U, Christensen DH, et al.
Circulation. Pub. online 29 Aug 2024.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Health-related quality of life of people with type 1 diabetes: an IMI2 SOPHIA post hoc analysis of FUTURE and ADJUNCT-ONE
Steenackers N, Sparsø T, Charleer S, et al.
Diabetes Obes Metab. Pub. online 27 Aug 2024.
Leggi
Relationship between sensor-detected hypoglycemia and patient-reported hypoglycemia in people with type 1 and insulin-treated type 2 diabetes: the Hypo-METRICS study
Divilly P, Martine-Edith G, Zaremba N, et al.
Diabetes Care. Pub. online 29 Aug 2024.
Leggi
Achieving normoglycaemia with tirzepatide: post hoc exploratory analysis of the SURPASS J-mono and J-combo studies
Fujihara K, Matsubayashi Y, Kitazawa M, et al.
Diabetes Obes Metab. Pub. online 27 Aug 2024.
Leggi
Fasting or 2-hour postprandial plasma glycemic criteria for gestational diabetes mellitus are associated with distinct adverse outcomes
Song Q, Song X, Li L, Ding H
BMC Pregnancy Childbirth. Pub. online 30 Aug 2024.
Leggi
Cardiovascular, kidney and safety outcomes with glp-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis
Neuen BL, Fletcher RA, Heath L, et al.
Circulation. Pub. online 30 Aug 2024.
Leggi
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Mahaffey KW, Tuttle KR, Arici M, et al.
Eur Heart J. Pub. online 30 Aug 2024.
Leggi
Machine learning-based reproducible prediction of type 2 diabetes subtypes
Tanabe H, Sato M, Miyake A, et al.
Diabetologia. Pub. online 21 Aug 2024.
Leggi
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes
Astbury NM
Diabetes Obes Metab. Pub. online 19 Aug 2024.
Leggi
Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: a population-based cohort study
Hong B, Bea S, Ko HY, et al.
Ann Intern Med. Pub. online 27 Aug 2024.
Leggi